Portage Biotech stock soars on promising preclinical results By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Should l Buy ?
Source: Investing.com
Portage Biotech's Breakthrough: Portage Biotech Inc's shares surged 33.9% after confirming preclinical efficacy data for PORT-7, a potential treatment for mesothelioma that outperformed existing therapies and is set to enter first-in-human trials.
Innovative Combination Therapy: The company is also exploring the combination of PORT-6 with PORT-7 to enhance anti-tumor responses, aiming to address immune resistance in aggressive cancers, as highlighted at the AACR Annual Meeting.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
